Apnimed (APMD) vs Candel Therapeutics (CADL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Apnimed is the larger company by market cap ($776.9 million vs $746.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APMD | CADL |
|---|---|---|
| Share price | $18.66 | $9.76 |
| Market cap | $776.93M | $746.82M |
| 1-day change | +2.43% | +1.04% |
| YTD return | — | +70.97% |
| 1-year return | — | +53.33% |
| 5-year return | — | -1.73% |
| P/E ratio (TTM) | 2.58 | — |
| EPS (TTM) | $7.22 | $-1.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.29 | $14.00 |
| 52-week low | $16.12 | $4.35 |
| Distance from 52-week high | -47.12% | -30.29% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +169.69% | +122.85% |
| Average volume | 552.07K | 1.21M |
| Shares outstanding | 41.63M | 76.52M |
| Employees | 81 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Apnimed
APMD stock →Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
APMD vs CADL FAQ
Which is bigger, Apnimed or Candel Therapeutics?
Apnimed (APMD) is larger, with a market capitalization of $776.93M compared with $746.82M for Candel Therapeutics (CADL).
Are Apnimed and Candel Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Apnimed and Biotechnology: Biological Products (No Diagnostic Substances) for Candel Therapeutics.